Andere Sprachen AlzeCure Pharma AB

Aktien

A2N951

SE0010133785

ALZCUR

Verzögert Nasdaq Stockholm Andere Börsenplätze 09:00:03 16.05.2024			% 5 Tage	% 1. Jan.
1,8 ^SEK	+0,84 %		0,00 %	-42,60 %

14.05.	AlzeCure Pharma AB (publ) genehmigt die Wahl von Jan Lundberg als neues ordentliches Mitglied des Verwaltungsrats	CI
25.04.	AlzeCure Pharma AB (publ) meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member	15.05.
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	14.05.
Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024	14.05.
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application	13.05.
AlzeCure Pharma publishes prospectus	29.04.
AlzeCure publishes its interim report for January – March 2024	25.04.
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25.04.
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board	10.04.
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	10.04.
AlzeCure Pharma publishes its Annual Report for 2023	04.04.
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024	03.04.
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	03.04.
AlzeCure to partake in Redeye Theme, Alzheimer on March 21	15.03.
AlzeCure to partake in Redeye Theme: Alzheimer on March 21	14.03.
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	07.03.
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer's conference	07.03.
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	05.03.
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer's	05.03.
AlzeCure's Alzheimer's project NeuroRestore ACD856 is granted an additional patent	29.02.
AlzeCure publishes its Year-end report for January – December 2023	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AlzeCure Pharma AB

Aktien

A2N951

SE0010133785

ALZCUR

Andere Sprachen

Filter